MedTrace Logo

Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer

NCT03990194 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-10-31

No results posted yet for this study

Summary

To improve the management of patients suffering from prostate cancer, Laboratoires BOUCHARA-RECORDATI wish to set up an observational study to document, in daily practice, and over a large population, the profile and clinical and biological follow-up of patients undergoing leuprorelin 5 mg implant as well as the conditions for implant placement. The evolution of these prostate cancer patients will be monitored on the basis of data available in daily practice, including testosterone values, PSA values, and factors that may influence disease progression, in order to objectify whether the observed results are consistent with those described in the clinical studies.

Conditions

Interventions

DRUG

Leuprolide Acetate

Administration of Leptoprol implant every 3 months

Sponsors & Collaborators

  • RECORDATI GROUP

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-03-01
Completion
2020-03-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03990194 on ClinicalTrials.gov